Multiple musculoskeletal conditions · Review · 2015
What did shockwave trials up to 2015 report for tendon, heel and shoulder problems?
This review sorted trials listed in a large physiotherapy database up to May 2015. By the authors' count, about eight in ten radial and focused shockwave trials reported a better result than placebo or another treatment. No serious side effects were reported.
- radial shockwave trials
- 26
- focused shockwave trials
- 81
- year of the search (to May)
- 2015
Good to know: A count of trial results across many conditions, not a combined analysis. Trials listed up to May 2015.
Schmitz C, Császár NB, Milz S, et al. British Medical Bulletin, 2015 · Read the paper ↗
How this study worked
What the trials used
- Review-level treatment pattern
- The review describes heterogeneous radial and focused devices, energy definitions, targets and schedules. Its proposed schedule (three sessions one week apart, 2,000 impulses each) is an inference from averages across the included trials’ protocols and selected studies, not a tested universal regimen.
- Energy and modality terminology
- The authors show that energy-flux-density thresholds used to label “low” versus “high” vary across publications, and argue that radial should not automatically be called low-energy or focused high-energy. Do not convert pressure units or assume devices are dose-equivalent.
Who took part
No single group of patients: trials in heel pain, Achilles and kneecap tendon pain, shoulder problems, tennis elbow and other conditions.
Side effects
The authors found no serious side effects reported in these trials.
All the numbers and the full appraisal
What the full paper reports.
Human randomized trials indexed in PEDro across multiple orthopedic indications; this review is a database-restricted evidence map and narrative synthesis, not a single patient cohort. Its trial counts include radial and focused ESWT records.
Direction of trial outcomes in PEDro1 reported outcome
Direction of trial outcomes in PEDro
Study-level positive/negative outcome classification trials; count and proportion
The authors classified 23/26 radial ESWT RCTs (88.5%) and 66/81 focused ESWT RCTs (81.5%) in PEDro as positive. “Positive” means statistically better than placebo or an alternative in the authors’ classification; it is not a pooled effect estimate, and condition-specific heterogeneity remains.
Analysis details and source
Vote-counting by trial; no pooled effect, participant denominator or certainty estimate. The counts are those stated in the Methods (Data extraction) and Discussion. The outcome column (O) of the review’s own Tables 2–3 does not match them: Table 2 marks 21 of the 26 radial trials positive and 5 negative, and Table 3 marks 62 of the 81 focused trials positive, 18 negative and one (Haake et al., ref. 87) unmarked.
PEDro scores and outcome direction1 reported outcome
PEDro scores and outcome direction
PEDro scale score points
Average PEDro score across included RCTs was 6.33 (SEM 0.17; range 1–9). The authors report nearly identical average quality across positive and negative outcome groups, although their Results report a statistically significant difference (P < 0.01) between the highest-scoring group (focused trials with negative outcome) and the lowest-scoring group (focused trials with positive outcome). The database sample and study-level classification do not establish treatment efficacy.
Analysis details and source
Descriptive review-level statistics from a selected database.
Serious adverse events1 reported outcome
Serious adverse events
Reported serious adverse events reports
The review reports no serious adverse events in the included studies. This is a report-based observation in a PEDro-selected corpus and does not establish that serious harms cannot occur or that all trials actively monitored them.
Analysis details and source
No pooled adverse-event denominator or standardized ascertainment is provided in this review.
Proposed treatment schedule1 reported outcome
Proposed treatment schedule
Review authors’ protocol recommendation sessions and impulses
The authors propose three sessions at one-week intervals, 2,000 impulses per session, and the highest tolerable energy flux density without local anesthesia. They explicitly base parts of this on averages across trials and selected “more is better” studies; the review did not test this schedule in a direct randomized comparison across conditions.
Analysis details and source
Historical hypothesis/recommendation; not a validated dose for every indication or device.
How treatment was delivered
The review describes heterogeneous radial and focused devices, energy definitions, targets and schedules. Its proposed schedule (three sessions one week apart, 2,000 impulses each) is an inference from averages across the included trials’ protocols and selected studies, not a tested universal regimen.
The authors show that energy-flux-density thresholds used to label “low” versus “high” vary across publications, and argue that radial should not automatically be called low-energy or focused high-energy. Do not convert pressure units or assume devices are dose-equivalent.
Authors state no serious adverse events were reported in the included PEDro trials. The review does not establish complete adverse-event surveillance or safety across devices and indications.
The review restricts its main evidence base to PEDro-listed RCTs; conclusions are valid only for that selected corpus and may omit relevant trials or other harms evidence.
No meta-analysis was conducted because conditions, devices, protocols and follow-up periods differed substantially.
Study-level positive/negative counts do not account for effect size, precision, multiplicity, publication bias or overlapping cohorts. This is an interpretation of the review’s vote-counting method.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- The review restricts its main evidence base to PEDro-listed RCTs; conclusions are valid only for that selected corpus and may omit relevant trials or other harms evidence.
- No meta-analysis was conducted because conditions, devices, protocols and follow-up periods differed substantially.
- Study-level positive/negative counts do not account for effect size, precision, multiplicity, publication bias or overlapping cohorts. This is an interpretation of the review’s vote-counting method.
Source-linked critical reading
Systematic clinical review
Technical source record
Complete full-text XML read; tables, figure captions, discussion and disclosures reviewed.
This older review describes many positive ESWT trials but does not combine their effects. It can help explain why protocols differ; it cannot determine the best device or dose for every condition.
What did PEDro-indexed randomized trials show about ESWT across orthopedic conditions, devices, protocols and adverse events?
Systematic review and narrative synthesis restricted primarily to RCTs listed in PEDro. The article searched PEDro to 17 May 2015 and grouped radial and focused trials; it did not meta-analyze because diagnoses, devices, protocols and follow-up differed substantially.
There is no single participant cohort. The review draws on RCT records across plantar fasciopathy, Achilles and patellar tendinopathy, shoulder disorders, lateral epicondylitis and other conditions. Counts of RCTs are not unique participant totals, and indications with few trials are explicitly underpowered for meaningful conclusions.
The review catalogues radial/focused generators, energy-flux-density definitions, impulse counts and session schedules in Tables 2–3. It argues that radial should not automatically be equated with low energy and focused with high energy. Local anesthesia and dose are discussed from selected studies, not a common randomized protocol.
Comparisons across the corpus included placebo, no treatment and alternative non-operative care. The review describes the comparative evidence but does not estimate one common comparator effect across conditions.
Authors classified 23/26 radial and 66/81 focused ESWT RCTs as positive. Mean PEDro score was 6.33 (SEM 0.17; range 1–9). These study-level summaries do not give a pooled patient outcome or account for the size and precision of each effect.
The authors report no evidence favoring either radial or focused ESWT overall and no statistically significant distribution difference by focused-device generation type. They propose three weekly-spaced sessions, 2,000 impulses each and highest tolerated EFD, but derive this partly from trial averages and selected dose studies rather than a direct universal dose trial.
No serious adverse events were reported in the included studies. Because the review does not provide a standardized pooled denominator or assurance of uniform active surveillance, this finding does not establish absence of rare or unreported harms.
The PEDro restriction, clinical heterogeneity, lack of meta-analysis and limited device corpus constrain generalization. Vote-counting positive trials can overstate certainty because it ignores magnitude, precision, multiplicity and publication bias. Several database proportions use selected denominators and historical search dates.
Use this review to explain the history of ESWT terminology and protocol variation. For a patient decision, current condition-specific comparisons and device-specific evidence are more relevant than the overall count of positive trials.
Future work should directly compare radial and focused devices at well-described matched doses, test dose schedules prospectively, report patient-important outcomes and harms consistently, and broaden searches beyond a single trial database.
Read the original article.
Efficacy and safety of extracorporeal shock wave therapy for orthopedic conditions: a systematic review on studies listed in the PEDro database.
Schmitz C, Császár NB, Milz S, Schieker M, Maffulli N, Rompe JD, Furia JP. · British medical bulletin · 2015
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →